Fumarate — Total Revenue
Biogen Fumarate — Total Revenue decreased by 1.5% to $288.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 16.4%, from $344.90M to $288.50M. Over 4 years (FY 2021 to FY 2025), Fumarate — Total Revenue shows a downward trend with a -11.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and sustained demand for the product line, while a decrease may signal market saturation, patent expiration, or increased competitive pressure.
Detailed definition
This metric represents the total gross revenue generated from the sale of fumarate-based pharmaceutical products within...
Peer comparison
Comparable to revenue segments for specific therapeutic franchises at other large-cap biopharmaceutical companies.
biib_segment_fumarate_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $578.50M | $619.50M | $611.40M | $537.90M | $534.70M | $476.80M | $447.90M | $382.70M | $400.40M | $405.00M | $400.70M | $381.80M | $418.00M | $390.90M | $404.40M | $344.90M | $405.90M | $382.80M | $292.90M | $288.50M |
| QoQ Change | — | +7.1% | -1.3% | -12.0% | -0.6% | -10.8% | -6.1% | -14.6% | +4.6% | +1.1% | -1.1% | -4.7% | +9.5% | -6.5% | +3.5% | -14.7% | +17.7% | -5.7% | -23.5% | -1.5% |
| YoY Change | — | — | — | — | -7.6% | -23.0% | -26.7% | -28.9% | -25.1% | -15.1% | -10.5% | -0.2% | +4.4% | -3.5% | +0.9% | -9.7% | -2.9% | -2.1% | -27.6% | -16.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's fumarate — total revenue?
- Biogen (BIIB) reported fumarate — total revenue of $288.50M in Q1 2026.
- How has Biogen's fumarate — total revenue changed year-over-year?
- Biogen's fumarate — total revenue decreased by 16.4% year-over-year, from $344.90M to $288.50M.
- What is the long-term trend for Biogen's fumarate — total revenue?
- Over 4 years (2021 to 2025), Biogen's fumarate — total revenue has grown at a -11.8% compound annual growth rate (CAGR), from $2.36B to $1.43B.
- What does fumarate — total revenue mean?
- The total sales revenue generated by the company's fumarate-based drug products.